Market Closed -
Toronto S.E.
04:00:00 2024-05-02 pm EDT
|
5-day change
|
1st Jan Change
|
2.38
CAD
|
+3.03%
|
|
+22.05%
|
+466.67%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
21.72
|
168.5
|
270.3
|
91.69
|
61.28
|
165.7
|
-
|
-
|
Enterprise Value (EV)
1 |
21.72
|
168.5
|
270.3
|
91.69
|
61.28
|
165.7
|
165.7
|
165.7
|
P/E ratio
|
-4.22
x
|
-13.8
x
|
-14.6
x
|
-3.93
x
|
-5.5
x
|
-10.5
x
|
-8.98
x
|
-9.65
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
284
x
|
90.4
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
284
x
|
90.4
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
8.3
x
|
4.66
x
|
7.17
x
|
4.3
x
|
1.49
x
|
9.92
x
|
-79.3
x
|
-9.52
x
|
Nbr of stocks (in thousands)
|
28,578
|
46,798
|
52,902
|
55,571
|
69,637
|
69,637
|
-
|
-
|
Reference price
2 |
0.7600
|
3.600
|
5.110
|
1.650
|
0.8800
|
2.380
|
2.380
|
2.380
|
Announcement Date
|
6/25/19
|
5/15/20
|
5/28/21
|
6/22/22
|
6/27/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.5833
|
1.833
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.727
|
-8.245
|
-17.4
|
-22.47
|
-16.3
|
-19.26
|
-20.25
|
-19.38
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,471.28%
|
-1,057.2%
|
Earnings before Tax (EBT)
1 |
-4.708
|
-8.277
|
-17.29
|
-22.58
|
-10.05
|
-15.97
|
-19.22
|
-18.8
|
Net income
1 |
-4.708
|
-8.277
|
-17.3
|
-22.58
|
-10.05
|
-15.75
|
-19.28
|
-18.87
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,304.3%
|
-1,029.17%
|
EPS
2 |
-0.1800
|
-0.2600
|
-0.3500
|
-0.4200
|
-0.1600
|
-0.2275
|
-0.2650
|
-0.2467
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/25/19
|
5/15/20
|
5/28/21
|
6/22/22
|
6/27/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.233
|
-4.897
|
-3.127
|
-4.33
|
-4.733
|
-4.921
|
-2.319
|
-4.459
|
-5.437
|
-4.777
|
-4.844
|
-5.213
|
-5.266
|
-5.318
|
-5.371
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.178
|
-4.807
|
-3.206
|
-4.155
|
-0.896
|
-1.141
|
-3.856
|
-2.882
|
-3.723
|
-4.977
|
-4.74
|
-5.213
|
-5.266
|
-5.318
|
-5.371
|
Net income
1 |
-8.2
|
-4.807
|
-3.206
|
-4.155
|
-0.896
|
-1.141
|
-3.856
|
-2.9
|
-3.723
|
-4.977
|
-4.74
|
-5.213
|
-5.266
|
-5.318
|
-5.371
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1500
|
-0.0900
|
-0.0600
|
-0.0700
|
-0.0100
|
-0.0200
|
-0.0600
|
-0.0400
|
-0.0500
|
-0.0700
|
-0.0675
|
-0.0700
|
-0.0700
|
-0.0600
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
2/9/22
|
6/22/22
|
8/15/22
|
11/4/22
|
2/7/23
|
6/27/23
|
7/28/23
|
11/14/23
|
2/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-46.5%
|
-76.6%
|
-34.1%
|
-101%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.0900
|
0.7700
|
0.7100
|
0.3800
|
0.5900
|
0.2400
|
-0.0300
|
-0.2500
|
Cash Flow per Share
2 |
-0.3100
|
-0.2800
|
-0.3100
|
-0.4300
|
-0.2000
|
-0.2300
|
0.2300
|
0.8100
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/25/19
|
5/15/20
|
5/28/21
|
6/22/22
|
6/27/23
|
-
|
-
|
-
|
Last Close Price
2.38
CAD Average target price
7
CAD Spread / Average Target +194.12% Consensus |
1st Jan change
|
Capi.
|
---|
| +466.67% | 121M | | +26.28% | 48.09B | | -3.99% | 40.43B | | +45.32% | 40.62B | | -6.20% | 28.36B | | +6.36% | 24.89B | | -21.47% | 19.01B | | +27.58% | 12.09B | | -2.75% | 11.8B | | -2.02% | 11.88B |
Other Biotechnology & Medical Research
|